Fhit-deficient normal and cancer cells are mitomycin C and UVC resistant

M Ottey1, S-Y Han, T Druck

  • 1Department of Microbiology-Immunology, Kimmel Cancer Center, Jefferson Medical College, Philadelphia, USA.

British Journal of Cancer
|October 21, 2004
PubMed

Insights

The fragile histidine triad gene (FHIT) suppresses tumors. FHIT-deficient cells show increased survival after DNA damage and higher mutation rates, suggesting a role in preventing malignant transformation.

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • The fragile histidine triad (FHIT) gene is a known tumor suppressor.
  • Understanding FHIT's function is crucial for cancer research.

Purpose of the Study:

  • To investigate the role of the FHIT gene in cell survival and DNA damage response.
  • To identify FHIT's functions in preventing malignant transformation.

Main Methods:

  • Comparing Fhit-negative and -positive human cancer cell clones and murine cell lines.
  • Subjecting cells to DNA-damaging agents (mitomycin C, UVC light).
  • Analyzing cell cycle kinetics, survival rates, and mutation frequencies.

Main Results:

  • Fhit-deficient cells exhibited significantly higher survival rates after UVC or mitomycin C treatment compared to Fhit-positive cells.
  • Fhit-deficient cells showed a more rapid decrease in DNA synthesis post-UVC exposure.
  • Surviving Fhit-deficient cells displayed increased transformation potential and a >5-fold rise in mutation frequency.

Conclusions:

  • FHIT deficiency leads to increased resistance to DNA damage and a higher propensity for malignant transformation.
  • The increased mutation burden in Fhit-deficient cells may contribute to their in vivo susceptibility to cancer development.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Mutations01:35

Mutations

Mutations are changes in the sequence of DNA. These changes can occur spontaneously or they can be induced by exposure to environmental factors. Mutations can be characterized in a number of different ways: whether and how they alter the amino acid sequence of the protein, whether they occur over a small or large area of DNA, and whether they occur in somatic cells or germline cells.
Chromosomal Alterations Are Large-Scale Mutations
While point mutations are changes in a single nucleotide in...